Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 7/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20177949 | 0.90 | FPR1 (0.52) | FPR1PKMHTTSMN1; SMN2NAAA | |
| SCHEMBL20177842 | 0.89 | FPR1 (0.53) | FPR1NAAAASAH1FPR2 | |
| SCHEMBL20177565 | 0.87 | FPR1 (0.43) | FPR1ALDH1A1KMT2APKMHTT | |
| SCHEMBL20177669 | 0.85 | FPR1 (0.43) | FPR1ALDH1A1KMT2APKMHTT | |
| SCHEMBL20177604 | 0.85 | FPR2 (0.47) | FPR1ALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL20177552 | 0.81 | EDNRB (0.40) | ALDH1A1KMT2APKMHTTSMN1; SMN2 | |
| SCHEMBL20177658 | 0.80 | FPR2 (0.48) | FPR1ALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL20177501 | 0.79 | FPR2 (0.47) | FPR1PKMHTTSMN1; SMN2NAAA | |
| SCHEMBL20177511 | 0.79 | FPR2 (0.67) | FPR1NAAAASAH1FPR2 | |
| SCHEMBL18578943 | 0.78 | FPR1 (0.55) | FPR1NAAAASAH1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018092916-A1 | NITROGEN-CONTAINING POLYCYCLIC HETEROCYCLIC DERIVATIVE | 宇部興産株式会社 | 2018-05-24 | — | — | WO | disclosed |